BACKGROUND: The @entity715 Prevention Trial was a primary prevention factorial trial that reported a reduction in the risk of @entity301 ( @entity301 ) with @entity1229 and/or @entity117 . This article examines compliance (duration of treatment) with @entity1229 treatment and whether @entity1229 has a retained effect. METHODS: Risk of @entity301 while complying with @entity1229 treatment was compared with risk of @entity301 in all @entity1 randomized to placebo. Simultaneously, risk of @entity301 in ex- @entity1229 users was compared with controls receiving placebo to determine the possibility of a retained effect. A second analysis, preserving the advantage of randomization, estimated the potential increase in the time to a @entity301 event in @entity1 randomized to active treatment compared with @entity1 randomized to placebo, if all @entity1 in both active and placebo groups had fully complied with the trial treatment. RESULTS: Risk of all @entity301 while complying with @entity1229 treatment was associated with a hazard ratio (HR) of 0.75 (95% confidence interval [CI], 0.60-0.94), which was lower than the HR obtained by intention-to-treat analysis (0.79; 95% CI, 0.65-0.96). Regarding fatal cases of @entity301 , the HR was 0.49 (95% CI, 0.32-0.75) while compliant with @entity1229 treatment, which is also lower than the HR obtained by intention-to-treat analysis (0.61, 95% CI, 0.43-0.85). Ex- @entity1229 users had a retained risk reduction of 23% for all @entity301 (0.77; 95% CI, 0.58-1.02) and of 34% for fatal events (0.66; 95% CI, 0.41-1.04). Expected survival time to a @entity301 event if @entity1 randomized to @entity1229 had fully complied with treatment was 1.39 times greater (95% CI, 1.12-1.69) than if @entity1 randomized to placebo had fully complied with placebo, whereas for fatal @entity301 the relative increase in survival time was 2.04 times greater for the former (95% CI, 1.43-2.86). CONCLUSIONS: Full compliance with @entity1229 treatment may lower by 50% the risk of fatal @entity301 . There is also evidence of a retained effect. These results strengthen previous evidence of the potential benefits of low-intensity oral anticoagulation with @entity1229 .

@entity715 prevention trial: compliance with XXXX treatment and investigation of a retained effect.

@entity1 :: ('9606', 'Species') :: ['participants', 'patients'] @entity301 :: ('MESH:D003327', 'Disease') :: ['CHD', 'coronary heart disease'] @entity117 :: ('MESH:D001241', 'Chemical') :: ['aspirin'] @entity715 :: ('MESH:D013927', 'Disease') :: ['Thrombosis'] @entity1229 :: ('MESH:D014859', 'Chemical') :: ['warfarin']
@entity1229 :: (MESH:D014859,Chemical) :: ['warfarin']
